Business

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 Injectable ZGGS18 and Gecacitinib Hydrochloride Tablets

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 Injectable ZGGS18 and Gecacitinib Hydrochloride Tablets

articleSuzhou Zelgen Biopharmaceuticals Co. Ltd. Class AAugust 21, 20254/news/announcement-on-voluntary-disclosure-of-obtaining-notice-of-approval-for-drug-clinical-trials-of-combination-of-injectable-zg005-injectable-zggs18-and-gecacitinib-hydrochloride-tablets
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 Injectable ZGGS18 and Gecacitinib Hydrochloride Tablets

About this update from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 Injectable ZGGS18 and Gecacitinib Hydrochloride TabletsThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A